Researcher Profiles

Return to member profile

Rajat Bannerji, MD, PhD

Publications since 2011

Mita, M. M. Joy, A. A. Mita, A. Sankhala, K. Jou, Y. M. Zhang, D. Statkevich, P. Zhu, Y. Yao, S. L. Small, K. Bannerji, R. Shapiro, C. L. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer, 14:169-176, . (PMID: 24393852)

Stephenson, J. J. Nemunaitis, J. Joy, A. A. Martin, J. C. Jou, Y. M. Zhang, D. Statkevich, P. Yao, S. L. Zhu, Y. Zhou, H. Small, K. Bannerji, R. Edelman, M. J. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung Cancer, 83:219-223, . (PMID: 24388167)

Gojo, I. Sadowska, M. Walker, A. Feldman, E. J. Iyer, S. P. Baer, M. R. Sausville, E. A. Lapidus, R. G. Zhang, D. Zhu, Y. Jou, Y. M. Poon, J. Small, K. Bannerji, R. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol, 72:897-908, . (PMID: 23949430, PMCID: PMC3784060)

Nemunaitis, J. J. Small, K. A. Kirschmeier, P. Zhang, D. Zhu, Y. Jou, Y. M. Statkevich, P. Yao, S. L. Bannerji, R. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med, 11:259, . (PMID: 24131779, PMCID: PMC3853718)

Johnson, A. J. Yeh, Y. Y. Smith, L. L. Wagner, A. J. Hessler, J. Gupta, S. Flynn, J. Jones, J. Zhang, X. Bannerji, R. Grever, M. R. Byrd, J. C. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia, 26:2554-2557, . (PMID: 22791353)

Zhang, D. Mita, M. Shapiro, G. I. Poon, J. Small, K. Tzontcheva, A. Kantesaria, B. Zhu, Y. Bannerji, R. Statkevich, P. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. Cancer Chemother Pharmacol, 70:891-898, . (PMID: 23053255)

Feldmann, G. Mishra, A. Bisht, S. Karikari, C. Garrido-Laguna, I. Rasheed, Z. Ottenhof, N. A. Dadon, T. Alvarez, H. Fendrich, V. Rajeshkumar, N. V. Matsui, W. Brossart, P. Hidalgo, M. Bannerji, R. Maitra, A. Nelkin, B. D. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther, 12:598-609, . (PMID: 21768779, PMCID: PMC3218385)